Pfizer Moves To Block Unichem Over Xeljanz Patent
This article was originally published in Scrip
Executive Summary
Pfizer has moved court against Unichem Laboratories seeking to block the Indian firm from allegedly infringing its patents concerning the rheumatoid arthritis therapy, tofacitinib (Xeljanz).
You may also be interested in...
Legal Wrangles: Foreign Firms Gaming The System In India?
Indian companies have cried foul over what they claim are "unethical" practices deployed by foreign firms in the legal arena, among others, to safeguard their "patent monopoly".
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.
India IPR Wheels Are Turning: Novartis, Bayer, Sun, Legal Heads Discuss Realities
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.